MAPK pathway
|
Chemoresistance
Radiation resistance
Enzyme therapy resistance
|
CH5126766 along with Eribulin
Dual inhibitors Cobimetinib and Trametinib
Brucein D (BD)
|
RAF/MEK inhibitor68
MEK1/2 and MEK 569
p38 pathway70
|
PI3K/AKT/mTOR pathway
|
Chemotherapy Resistance
Radiotherapy Resistance
|
Gigantol
Anilide Shikonin ester- M9.
AZD5363 alongside 3,3’-Diindoylmethane
Dietary phytochemicals
|
Akt 73-75
Luminal A breast cancer cells 76
|
STAT 3 pathway
|
Radiotherapy Resistance
Chemotherapy resistance
|
Resveratrol
Trastuzumab
6Br-6a
|
STAT3 77-79
|
Wnt/beta-catenin pathway
|
Chemoresistance
Radioresistance
Immunotherapy resistance
|
Tankyrase inhibitors such as XAV939
Introduction of truncated APC
|
Axin degradation64
Lack of APC64
|
Hedgehog pathway
|
Chemoresistance
Immunotherapy resistance
|
Smo inhibitors like Vismodegib,Sonidegib, Saridegib and Taladegib
|
Smo receptor80,81
|
Notch pathway
|
Chemoresistance
Immunotherapy resistance
|
Gamma-secretase inhibitors such as Z-Leu-Leu-Nle-CHO
Monoclonal antibodies like OMP-59R5
|
Gamma-secretase protein82,84
Notch 2/ Notch 3 receptors83
|